<DOC>
	<DOCNO>NCT01663389</DOCNO>
	<brief_summary>This phase 1 , non-randomized , open label , single-dose , two-period , cross-over study . This study utilize 14C radiolabeled GSK1322322 investigate recovery , excretion , pharmacokinetics GSK1322322 6 healthy adult male subject sample blood , urine , feces . Each subject participate study approximately 7 8 week i.e. , 30 day screen period , two dose period ( approximately 8 day ) follow visit . The subject admit clinical unit Day 1 first treatment period remain unit approximately 16 day end second treatment period . On Day 1 Period 1 , subject receive 14C radiolabeled GSK1322322 single therapeutic intravenous ( IV ) dose ( 1000 milligram [ mg ] ) . When total radioactivity &lt; 1 % administer dose subject , Period 2 dose begin ( approximately 8 day IV dose ) . On Day 1 Period 2 , subject receive single therapeutic oral solution dose ( 1200 mg ) . Blood , urine , bile fecal sample collect period . The subject may discharge unit early Day 8 Period 2 . Subjects visit study unit follow-up visit 7 10 day follow discharge unit .</brief_summary>
	<brief_title>A Study Investigate Recovery , Excretion , Pharmacokinetics 14C -GSK1322322 After Intravenous Oral Dose</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Healthy male subject 30 55 year age , body weight 60 80 kilogram ( kg ) history regular bowel movement Male subject female partner childbearing potential must agree use one contraception method first dose study medication final follow visit Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin = &lt; 1.5x upper limit normal QT interval Bazett 's correction formula ( QTcB ) &lt; 450 millisecond ( msec ) ; QTcB &lt; 480 msec subject Bundle Branch Block Available complete study return followup visit necessary Capable give write informed consent Any condition could interfere accurate assessment recovery radioactivity [ 14C ] Participation clinical trial involve administration radiolabeled 14Clabelled compound ( ) within last 12 month Any condition impairs absorption , distribution , metabolism excretion investigational product Subjects history cholecystectomy Subject receive total body radiation dose great 5.0 millisievert ( mSv ) exposure significant radiation 1 year dose The subject positive : drug/alcohol , Hepatitis , HIV screen Abuse alcohol History liver disease , know hepatic biliary abnormality The subject recently receive investigational product Donation 500 mL blood within 56 day period Unwillingness inability follow procedure outline protocol Use prescription nonprescription drug Subject mentally legally incapacitated History sensitivity heparin heparininduced thrombocytopenia Smoking history regular use tobacco nicotinecontaining product Unable refrain consumption red wine , Seville oranges , grapefruit grapefruit juice 7 day prior first dose History cardiac disease</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>mass balance</keyword>
	<keyword>radiolabel</keyword>
	<keyword>oral</keyword>
	<keyword>IV</keyword>
	<keyword>GSK1322322</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>antibiotic</keyword>
</DOC>